Skip to content

Disruption of memory reconsolidation of alcohol-related memory associations by propanolol - effects of alcohol and betablocker

Disruption of memory reconsolidation of alcohol-related memory associations by propanolol - effects of alcohol and betablocker

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2007-005929-30-NL
Enrollment
60
Registered
2007-11-06
Start date
2008-01-16
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

alcohol abuse MedDRA version: 9.1 Level: LLT Classification code 10001584 Term: Alcohol abuse

Interventions

Trade Name: Centrafarm Product Code: RVG 55618 Pharmaceutical Form: Tablet INN or Proposed INN: PROPRANOLOL CAS Number: 525666 Concentration unit: mg milligram(s) Concentration type: equal Concentrat

Sponsors

Maastricht University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: males age >= 18 recent history of heavy alcohol use 15–50 European standard drinks per week (European standard drinks contain about 10 g pure alcohol) Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: No history of treatment for addiction. No use of medication that may interact with alcohol. No contra-indications for propranolol: sick-sinussyndrome, second- and thirddegree atrioventriculair-block, hypotension, cardiogene shock, clinically relevant sinusbradycardie, asthma and othetr obstructive longdiseases or untreated hartfailure.

Design outcomes

Primary

MeasureTime frame
Main Objective: Weakening of previous learned positive associations with alcohol by propranolol administered immediately upon retrieval of these associative memories.;Secondary Objective: ;Primary end point(s): 1. scores on computertasks, comparison of scores from placebo and propranolol treatment. 2. subjective craving-scores using VAS-questionaires after completion of the computertasks

Countries

Netherlands

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026